about
RetinoblastomaChemotherapy for children with medulloblastomaParental smoking, maternal alcohol, coffee and tea consumption during pregnancy and childhood malignant central nervous system tumours: the ESCALE study (SFCE)Dysmorphic phenotype and neurological impairment in 22 retinoblastoma patients with constitutional cytogenetic 13q deletionSubgroup-specific structural variation across 1,000 medulloblastoma genomesPhase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP studyRetinoblastoma: Update on Current Management.Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Photodynamic efficiency of diethylene glycol-linked glycoconjugated porphyrins in human retinoblastoma cells.Chemothermotherapy in the management of retinoblastoma.[Diode laser thermotherapy and chemothermotherapy in the treatment of retinoblastoma]Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.[Central neurological manifestations during chemotherapy in children][Functional results of retinoblastoma treatment with local treatment used in isolation or associated with chemotherapy].[Retinoblatoma: a review]Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.[Cancer in children: epidemiologic, diagnostic and therapeutic characteristics].Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.Brainstem gliomas in children and adults.Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.[Childhood medulloblastoma].Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?The readability of information and consent forms in clinical research in France.Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma.Neuropathological and neuroradiological spectrum of pediatric malignant gliomas: correlation with outcome.Osteosarcoma following retinoblastoma: age at onset and latency period.Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie.A proposal for an international retinoblastoma staging system.The state of research into children with cancer across Europe: new policies for a new decade.Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy.Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy.[Retinoblastoma update].A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1Parental consent in paediatric clinical research.Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?
P50
Q21558539-BB228194-5529-4FB1-9BC7-C86F083E10C7Q24186770-13E09DC5-328D-4090-8AE9-859E8970F58DQ24651277-B789D59E-1FAB-452A-9D58-79D24F7377D0Q28142341-D27E6E5D-C363-4570-B9F3-363FF2C7E3BFQ28271811-36593654-EAE4-4440-B960-DF2A5152B93AQ28359347-EBB81BCD-C27A-4537-8400-C781B69F45AFQ30101072-31244EA4-D231-47AF-AE09-5BAAE04437FCQ30234441-5D34C8B8-0166-4AB0-A2A3-D644EF955D88Q30813410-9D5C8E10-64A1-4BF6-913A-6C7F536FF876Q31066339-50FA4C76-1286-48F8-B63B-BA387D65F719Q31136525-FD4F42DD-0CEA-4901-8E46-FED0FAAE1630Q32073310-9E601024-3FF9-4069-A5BF-B8129F01F77CQ33188128-C5D49686-054B-4A53-A87D-1E5E93640471Q33224665-D89AF8CF-07EA-46CF-8302-3DF1D42A370AQ33255160-23E5D629-A3DC-4247-8D50-EB4CCD86AFBAQ33273354-6D9DCF61-7832-4FE6-AB11-7626348326ACQ33340392-3CD98174-08EC-47C1-B4FE-FCC7BE2DB24CQ33345746-31879F08-50BD-4E97-827A-DD696302EB0CQ33368246-CA50F9C9-37A1-49E3-854D-0771761324D4Q33374512-468C31F3-4BF4-4B12-BA64-8918941654A1Q33381221-BB79C92B-4694-4BB8-906A-358071F3D757Q33383410-D90FE674-B1A5-48F5-991C-4267CC287C04Q33400443-C06D9444-59AB-46CD-83A3-603472058C89Q33490131-3F32C5BC-E916-4F02-89FD-5445008BD036Q33496229-80C39132-8314-4256-BE18-BE8B6D8FC923Q33582098-38EE2E56-817F-4D12-A966-AE06308230CDQ33582098-4C987FF4-33F8-4295-BF82-6F0BBD6A1B0CQ33733192-6DC2BA74-7FE4-475A-92C7-30BA25686C2FQ33757273-B6E4C8C5-8A5A-4965-8827-109C7EE6B141Q33835128-81458521-5527-4957-8279-C5FCB92FA880Q34306026-2F5DD226-2B7D-4B53-8043-3D866506A014Q34548626-D8DF6F5B-EB5A-4CBC-9379-6F54162B735BQ34563469-3BAF9F04-615F-4977-B15F-FA7F214AAD3FQ35572738-3F028121-1694-42AF-B832-FDDB7591C1F4Q35670831-B50820A2-A377-4AC3-986F-2DD550ADCA58Q35795658-CC6403EC-5CBC-4E2A-B353-F2A56B991475Q35872174-AD4A381B-6DE2-40AC-B0F2-1E19852E8A8EQ35939441-5EE0BEA6-E6CD-48E5-A818-27BC1842A5E1Q36152844-298A2651-B3ED-46E4-BFB8-336728697B54Q36202044-F721248B-F413-456B-BC1D-BD3D2003BFB9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
François Doz
@af
François Doz
@an
François Doz
@ast
François Doz
@bar
François Doz
@br
François Doz
@ca
François Doz
@co
François Doz
@cs
François Doz
@cy
François Doz
@da
type
label
François Doz
@af
François Doz
@an
François Doz
@ast
François Doz
@bar
François Doz
@br
François Doz
@ca
François Doz
@co
François Doz
@cs
François Doz
@cy
François Doz
@da
prefLabel
François Doz
@af
François Doz
@an
François Doz
@ast
François Doz
@bar
François Doz
@br
François Doz
@ca
François Doz
@co
François Doz
@cs
François Doz
@cy
François Doz
@da
P106
P21
P31
P496
0000-0001-9286-4831